Global Bispecific Antibodies Market
Global Bispecific Antibodies Market

Bispecific Antibodies Comprehensive Study by Drug (Blinatumab, Catumaxomab, Duligotumab), Indication (Cancer, Infectious Disease, Inflammatory and Autoimmune Disorders, CNS Disorders), Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Players and Region - Global Market Outlook to 2026

Bispecific Antibodies Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 224 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Bispecific Antibodies Market?

Bispecific antibody (BsAb) is an artificial protein made up of fragments from two monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. BsAb has a broader range of uses, including lung, breast, and colon cancer. The major players in the global bispecific antibodies market are concentrating their efforts on developing and launching new products. These medications are still under development and are expected to have a promising future. Manufacturers are always attempting to improve these items in response to the increased occurrence of cancer, which necessitates better therapeutic treatment.

The market study is being classified and major geographies with country level break-up.

Amgen, Inc. (United States), Bayer AG (Germany), Dow Pharmaceutical Solutions (United States), ImmunGene, Inc. (United States), Immunocore Limited (United Kingdom), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer, Inc. (United States) and F. Hoffmann-La Roche AG (Switzerland) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, and collaborations as their preferred strategies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Bispecific Antibodies market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Bispecific Antibodies market by Type, Application and Region.

On the basis of geography, the market of Bispecific Antibodies has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Prevalence of Different Types of Cancer
  • Manufacturers in the market are Collaborating with Regional Biotech Companies for the Development of Bispecific Antibodies

Market Trend
  • Increase in Advanced Research Activities

Restraints
  • Technical Complexity associated with the Treatment Procedure (detection) of Bispecific Antibodies

Opportunities
  • Favorable Initiatives Taken by the Federal Government
  • Increasing Healthcare Access and Awareness in Developing Region

Challenges
  • Lack of Awareness


In December 2020, Pfizer reported positive clinical data for BCMA-CD3 bispecific antibody in multiple myeloma., and In January 2019, the Chinese Academy of Medical Sciences & Peking Union Medical College developed a new bispecific aptamer that enhances immune cytotoxicity against MUC1-positive tumor cells.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Government Regulatory and Research Organizations, Bispecific Antibodies Provider and End-Use Industries

Frequently Asked Questions (FAQ):

1. Which factors would majorly drive the Bispecific Antibodies Market?
"Rising Prevalence of Different Types of Cancer " is seen as one of major growth factors of Bispecific Antibodies Market in years to come.

2. Can we have customized study for Bispecific Antibodies Market?
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

3. Which region will lead the Global Bispecific Antibodies Market?
will lead the Bispecific Antibodies Market.
Report Objectives / Segmentation Covered
By Drug
  • Blinatumab
  • Catumaxomab
  • Duligotumab

By Indication
  • Cancer
  • Infectious Disease
  • Inflammatory and Autoimmune Disorders
  • CNS Disorders

By Distribution Channel
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Different Types of Cancer
      • 3.2.2. Manufacturers in the market are Collaborating with Regional Biotech Companies for the Development of Bispecific Antibodies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness
    • 3.4. Market Trends
      • 3.4.1. Increase in Advanced Research Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bispecific Antibodies, by Drug, Indication, Distribution Channel and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bispecific Antibodies (Value)
      • 5.2.1. Global Bispecific Antibodies by: Drug (Value)
        • 5.2.1.1. Blinatumab
        • 5.2.1.2. Catumaxomab
        • 5.2.1.3. Duligotumab
      • 5.2.2. Global Bispecific Antibodies by: Indication (Value)
        • 5.2.2.1. Cancer
        • 5.2.2.2. Infectious Disease
        • 5.2.2.3. Inflammatory and Autoimmune Disorders
        • 5.2.2.4. CNS Disorders
      • 5.2.3. Global Bispecific Antibodies by: Distribution Channel (Value)
        • 5.2.3.1. Hospital pharmacies
        • 5.2.3.2. Retail pharmacies
        • 5.2.3.3. Online pharmacies
      • 5.2.4. Global Bispecific Antibodies Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Bispecific Antibodies: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amgen, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bayer AG (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dow Pharmaceutical Solutions (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. ImmunGene, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Immunocore Limited (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. F. Hoffmann-La Roche AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Bispecific Antibodies Sale, by Drug, Indication, Distribution Channel and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bispecific Antibodies (Value)
      • 7.2.1. Global Bispecific Antibodies by: Drug (Value)
        • 7.2.1.1. Blinatumab
        • 7.2.1.2. Catumaxomab
        • 7.2.1.3. Duligotumab
      • 7.2.2. Global Bispecific Antibodies by: Indication (Value)
        • 7.2.2.1. Cancer
        • 7.2.2.2. Infectious Disease
        • 7.2.2.3. Inflammatory and Autoimmune Disorders
        • 7.2.2.4. CNS Disorders
      • 7.2.3. Global Bispecific Antibodies by: Distribution Channel (Value)
        • 7.2.3.1. Hospital pharmacies
        • 7.2.3.2. Retail pharmacies
        • 7.2.3.3. Online pharmacies
      • 7.2.4. Global Bispecific Antibodies Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bispecific Antibodies: by Drug(USD Million)
  • Table 2. Bispecific Antibodies Blinatumab , by Region USD Million (2015-2020)
  • Table 3. Bispecific Antibodies Catumaxomab , by Region USD Million (2015-2020)
  • Table 4. Bispecific Antibodies Duligotumab , by Region USD Million (2015-2020)
  • Table 5. Bispecific Antibodies: by Indication(USD Million)
  • Table 6. Bispecific Antibodies Cancer , by Region USD Million (2015-2020)
  • Table 7. Bispecific Antibodies Infectious Disease , by Region USD Million (2015-2020)
  • Table 8. Bispecific Antibodies Inflammatory and Autoimmune Disorders , by Region USD Million (2015-2020)
  • Table 9. Bispecific Antibodies CNS Disorders , by Region USD Million (2015-2020)
  • Table 10. Bispecific Antibodies: by Distribution Channel(USD Million)
  • Table 11. Bispecific Antibodies Hospital pharmacies , by Region USD Million (2015-2020)
  • Table 12. Bispecific Antibodies Retail pharmacies , by Region USD Million (2015-2020)
  • Table 13. Bispecific Antibodies Online pharmacies , by Region USD Million (2015-2020)
  • Table 14. South America Bispecific Antibodies, by Country USD Million (2015-2020)
  • Table 15. South America Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 16. South America Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 17. South America Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 18. Brazil Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 19. Brazil Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 20. Brazil Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 21. Argentina Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 22. Argentina Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 23. Argentina Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 24. Rest of South America Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 25. Rest of South America Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 26. Rest of South America Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 27. Asia Pacific Bispecific Antibodies, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 29. Asia Pacific Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 30. Asia Pacific Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 31. China Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 32. China Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 33. China Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 34. Japan Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 35. Japan Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 36. Japan Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 37. India Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 38. India Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 39. India Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 40. South Korea Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 41. South Korea Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 42. South Korea Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 43. Taiwan Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 44. Taiwan Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 45. Taiwan Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 46. Australia Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 47. Australia Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 48. Australia Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 52. Europe Bispecific Antibodies, by Country USD Million (2015-2020)
  • Table 53. Europe Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 54. Europe Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 55. Europe Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 56. Germany Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 57. Germany Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 58. Germany Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 59. France Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 60. France Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 61. France Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 62. Italy Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 63. Italy Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 64. Italy Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 65. United Kingdom Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 66. United Kingdom Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 67. United Kingdom Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 68. Netherlands Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 69. Netherlands Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 70. Netherlands Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 71. Rest of Europe Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 72. Rest of Europe Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 73. Rest of Europe Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 74. MEA Bispecific Antibodies, by Country USD Million (2015-2020)
  • Table 75. MEA Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 76. MEA Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 77. MEA Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 78. Middle East Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 79. Middle East Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 80. Middle East Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 81. Africa Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 82. Africa Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 83. Africa Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 84. North America Bispecific Antibodies, by Country USD Million (2015-2020)
  • Table 85. North America Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 86. North America Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 87. North America Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 88. United States Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 89. United States Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 90. United States Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 91. Canada Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 92. Canada Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 93. Canada Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 94. Mexico Bispecific Antibodies, by Drug USD Million (2015-2020)
  • Table 95. Mexico Bispecific Antibodies, by Indication USD Million (2015-2020)
  • Table 96. Mexico Bispecific Antibodies, by Distribution Channel USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Bispecific Antibodies: by Drug(USD Million)
  • Table 107. Bispecific Antibodies Blinatumab , by Region USD Million (2021-2026)
  • Table 108. Bispecific Antibodies Catumaxomab , by Region USD Million (2021-2026)
  • Table 109. Bispecific Antibodies Duligotumab , by Region USD Million (2021-2026)
  • Table 110. Bispecific Antibodies: by Indication(USD Million)
  • Table 111. Bispecific Antibodies Cancer , by Region USD Million (2021-2026)
  • Table 112. Bispecific Antibodies Infectious Disease , by Region USD Million (2021-2026)
  • Table 113. Bispecific Antibodies Inflammatory and Autoimmune Disorders , by Region USD Million (2021-2026)
  • Table 114. Bispecific Antibodies CNS Disorders , by Region USD Million (2021-2026)
  • Table 115. Bispecific Antibodies: by Distribution Channel(USD Million)
  • Table 116. Bispecific Antibodies Hospital pharmacies , by Region USD Million (2021-2026)
  • Table 117. Bispecific Antibodies Retail pharmacies , by Region USD Million (2021-2026)
  • Table 118. Bispecific Antibodies Online pharmacies , by Region USD Million (2021-2026)
  • Table 119. South America Bispecific Antibodies, by Country USD Million (2021-2026)
  • Table 120. South America Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 121. South America Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 122. South America Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 123. Brazil Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 124. Brazil Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 125. Brazil Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 126. Argentina Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 127. Argentina Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 128. Argentina Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 129. Rest of South America Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 130. Rest of South America Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 131. Rest of South America Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 132. Asia Pacific Bispecific Antibodies, by Country USD Million (2021-2026)
  • Table 133. Asia Pacific Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 134. Asia Pacific Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 135. Asia Pacific Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 136. China Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 137. China Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 138. China Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 139. Japan Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 140. Japan Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 141. Japan Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 142. India Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 143. India Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 144. India Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 145. South Korea Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 146. South Korea Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 147. South Korea Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 148. Taiwan Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 149. Taiwan Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 150. Taiwan Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 151. Australia Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 152. Australia Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 153. Australia Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 156. Rest of Asia-Pacific Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 157. Europe Bispecific Antibodies, by Country USD Million (2021-2026)
  • Table 158. Europe Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 159. Europe Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 160. Europe Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 161. Germany Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 162. Germany Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 163. Germany Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 164. France Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 165. France Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 166. France Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 167. Italy Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 168. Italy Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 169. Italy Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 170. United Kingdom Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 171. United Kingdom Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 172. United Kingdom Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 173. Netherlands Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 174. Netherlands Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 175. Netherlands Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 176. Rest of Europe Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 177. Rest of Europe Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 178. Rest of Europe Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 179. MEA Bispecific Antibodies, by Country USD Million (2021-2026)
  • Table 180. MEA Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 181. MEA Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 182. MEA Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 183. Middle East Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 184. Middle East Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 185. Middle East Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 186. Africa Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 187. Africa Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 188. Africa Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 189. North America Bispecific Antibodies, by Country USD Million (2021-2026)
  • Table 190. North America Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 191. North America Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 192. North America Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 193. United States Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 194. United States Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 195. United States Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 196. Canada Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 197. Canada Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 198. Canada Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 199. Mexico Bispecific Antibodies, by Drug USD Million (2021-2026)
  • Table 200. Mexico Bispecific Antibodies, by Indication USD Million (2021-2026)
  • Table 201. Mexico Bispecific Antibodies, by Distribution Channel USD Million (2021-2026)
  • Table 202. Research Programs/Design for This Report
  • Table 203. Key Data Information from Secondary Sources
  • Table 204. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bispecific Antibodies: by Drug USD Million (2015-2020)
  • Figure 5. Global Bispecific Antibodies: by Indication USD Million (2015-2020)
  • Figure 6. Global Bispecific Antibodies: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Bispecific Antibodies Share (%), by Country
  • Figure 8. Asia Pacific Bispecific Antibodies Share (%), by Country
  • Figure 9. Europe Bispecific Antibodies Share (%), by Country
  • Figure 10. MEA Bispecific Antibodies Share (%), by Country
  • Figure 11. North America Bispecific Antibodies Share (%), by Country
  • Figure 12. Global Bispecific Antibodies share by Players 2020 (%)
  • Figure 13. Global Bispecific Antibodies share by Players (Top 3) 2020(%)
  • Figure 14. Global Bispecific Antibodies share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Amgen, Inc. (United States) Revenue: by Geography 2020
  • Figure 18. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 20. Dow Pharmaceutical Solutions (United States) Revenue, Net Income and Gross profit
  • Figure 21. Dow Pharmaceutical Solutions (United States) Revenue: by Geography 2020
  • Figure 22. ImmunGene, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. ImmunGene, Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Immunocore Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. Immunocore Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 30. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. F. Hoffmann-La Roche AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 33. F. Hoffmann-La Roche AG (Switzerland) Revenue: by Geography 2020
  • Figure 34. Global Bispecific Antibodies: by Drug USD Million (2021-2026)
  • Figure 35. Global Bispecific Antibodies: by Indication USD Million (2021-2026)
  • Figure 36. Global Bispecific Antibodies: by Distribution Channel USD Million (2021-2026)
  • Figure 37. South America Bispecific Antibodies Share (%), by Country
  • Figure 38. Asia Pacific Bispecific Antibodies Share (%), by Country
  • Figure 39. Europe Bispecific Antibodies Share (%), by Country
  • Figure 40. MEA Bispecific Antibodies Share (%), by Country
  • Figure 41. North America Bispecific Antibodies Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Amgen, Inc. (United States)
  • Bayer AG (Germany)
  • Dow Pharmaceutical Solutions (United States)
  • ImmunGene, Inc. (United States)
  • Immunocore Limited (United Kingdom)
  • Merck & Co., Inc. (United States)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (United States)
  • F. Hoffmann-La Roche AG (Switzerland)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation